Company logo

VKTX - Viking Therapeutics, Inc.

NASDAQ -> Healthcare -> Biotechnology
San Diego, United States
Type: Equity

VKTX price evolution
VKTX
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Current assets
Cash $55.55 $37.22 $69.55 $18.39
Short term investments $306.56 $339.06 $323.4 $117.3
Net receivables
Inventory
Total current assets $367.23 $381.3 $399.37 $149.47
Long term investments
Property, plant & equipment $1.13 $1.2 $1.27 $1.35
Goodwill & intangible assets
Total noncurrent assets $1.26 $1.36 $1.32 $1.43
Total investments $306.56 $339.06 $323.4 $117.3
Total assets $368.49 $382.66 $400.69 $150.9
Current liabilities
Accounts payable $7.51 $5.71 $5.61 $3.8
Deferred revenue
Short long term debt $0.32 $0.32 $0.31 $0.31
Total current liabilities $19.14 $13.4 $13.48 $15.65
Long term debt $0.94 $1.02 $1.1 $1.18
Total noncurrent liabilities $0.94 $1.02 $1.1 $1.18
Total debt $1.26 $1.34 $1.41 $1.49
Total liabilities $20.07 $14.42 $14.58 $16.83
Shareholders' equity
Retained earnings -$377.94 -$353.34 -$330.81 -$311.58
Other shareholder equity -$0.39 -$0.91 -$1.04 -$0.62
Total shareholder equity $348.42 $368.24 $386.12 $134.06
(in millions $) 31 Dec 2023 31 Jan 2023 31 Jan 2022 31 Jan 2021
Current assets
Cash $55.55 $36.63 $26.37 $29.1
Short term investments $306.56 $118.85 $175.73 $219.27
Net receivables
Inventory
Total current assets $367.23 $167.04 $210.53 $256.1
Long term investments
Property, plant & equipment $1.13 $1.42 $0.03 $0.3
Goodwill & intangible assets
Total noncurrent assets $1.26 $1.49 $0.13 $0.4
Total investments $306.56 $118.85 $175.73 $219.27
Total assets $368.49 $168.53 $210.66 $256.5
Current liabilities
Accounts payable $7.51 $8.53 $1.44 $4
Deferred revenue
Short long term debt $0.32 $0.3 $0.03 $0.33
Total current liabilities $19.14 $21.95 $8.78 $12.1
Long term debt $0.94 $1.26 $0.03
Total noncurrent liabilities $0.94 $1.26 $0.03
Total debt $1.26 $1.56 $0.03 $0.36
Total liabilities $20.07 $23.21 $8.78 $12.2
Shareholders' equity
Retained earnings -$377.94 -$292.05 -$223.18 -$168.2
Other shareholder equity -$0.39 -$1.1 -$0.55 -$0.1
Total shareholder equity $348.42 $145.32 $201.88 $244.34
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $20.5 $18.38 $13.92 $11.01
Selling, general & administrative $8.78 $8.89 $9.82 $9.53
Total operating expenses $29.29 $27.27 $23.74 $20.54
Operating income -$29.29 -$27.27 -$23.74 -$20.54
Income from continuing operations
EBIT -$24.61 -$22.53 -$19.23 -$19.53
Income tax expense
Interest expense
Net income
Net income -$24.61 -$22.53 -$19.23 -$19.53
Income (for common shares) -$24.61 -$22.53 -$19.23 -$19.53
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $63.81 $54.23 $44.98 $31.93
Selling, general & administrative $37.02 $16.12 $10.7 $10.73
Total operating expenses $100.83 $70.36 $55.68 $42.66
Operating income -$100.83 -$70.36 -$55.68 -$42.66
Income from continuing operations
EBIT -$85.89 -$68.87 -$54.99 -$39.49
Income tax expense
Interest expense
Net income
Net income -$85.89 -$68.87 -$54.99 -$39.49
Income (for common shares) -$85.89 -$68.87 -$54.99 -$39.49
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Net income -$24.61 -$22.53 -$19.23 -$19.53
Operating activities
Depreciation $0.07 $0.07 $0.07 $0.07
Business acquisitions & disposals
Stock-based compensation $4.08 $4.48 $4.62 $3.57
Total cash flows from operations -$17.64 -$19.66 -$11.44 -$24.64
Investing activities
Capital expenditures
Investments $35.73 -$12.53 -$204.48 $2.2
Total cash flows from investing $35.73 -$12.53 -$204.48 $2.2
Financing activities
Dividends paid
Sale and purchase of stock $0.19 -$0.07 $272.45 $5.93
Net borrowings
Total cash flows from financing $0.19 -$0.07 $267.08 $4.18
Effect of exchange rate $0.05 -$0.07 -$0 -$0.01
Change in cash and equivalents $18.28 -$32.27 $51.16 -$18.26
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$85.89 -$68.87 -$54.99 -$39.49
Operating activities
Depreciation $0.29 $0.29 $0.3 $0.28
Business acquisitions & disposals
Stock-based compensation $16.75 $8.67 $6.1 $5.82
Total cash flows from operations -$73.38 -$48.4 -$47.59 -$21.78
Investing activities
Capital expenditures
Investments -$179.09 $54.75 $37.96 $41.57
Total cash flows from investing -$179.09 $54.75 $37.96 $41.57
Financing activities
Dividends paid
Sale and purchase of stock $278.5 $5.72 $7.63 $1.27
Net borrowings
Total cash flows from financing $271.38 $4.16 $6.88 $0.95
Effect of exchange rate -$0.03 -$0.26
Change in cash and equivalents $18.91 $10.52 -$2.75 $20.74
Fundamentals
Market cap $8.21B
Enterprise value $8.16B
Shares outstanding 100.11M
Revenue $0.00
EBITDA -$85.60M
EBIT -$85.89M
Net Income -$85.89M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -95.57
EV/Sales N/A
EV/EBITDA -95.27
EV/EBIT -94.94
P/S ratio N/A
P/B ratio 23.54
Book/Share 3.48
Cash/Share 0.55
EPS -$0.86
ROA -26.37%
ROE -27.78%
Debt/Equity 0.06
Net debt/EBITDA 0.41
Current ratio 19.19
Quick ratio 19.19